Freenome and Exact Sciences Enter Strategic Partnership
Freenome, a leader in early cancer detection through advanced biotechnology, has taken a significant step forward by signing an exclusive license agreement with Exact Sciences. This collaboration primarily focuses on the commercialization of Freenome's innovative blood-based screening test designed for colorectal cancer (CRC). The deal is estimated to be worth up to $885 million, primarily contingent on reaching specific regulatory approvals and milestones.
Enhancing Colorectal Cancer Detection
Freenome's cutting-edge colorectal cancer test has recently advanced with the submission of its final module to the FDA. Anticipated approval and launch of the product are foreseen in 2026. This blood test aims to harness the power of real-world patient data and multimodal molecular information, utilizing AI and machine learning to enhance the accuracy of cancer detection.
Strategic Benefits of the Partnership
This agreement is crucial for Freenome as it allows the company to maintain its rights for the blood test when used alongside other cancer screening tests, notably those targeting lung cancer and several others the company is developing.
Exact Sciences is well-positioned to accelerate the market introduction of Freenome’s CRC blood test, leveraging its existing relationships with around 400 health systems, 865 in-network payers, and over 260,000 ordering physicians. This established infrastructure is expected to facilitate wider accessibility for patients, complementing the introduction of Freenome's advanced screening methods.
Leadership Voices on the Collaboration
"We are thrilled to partner with Exact Sciences, marking a pivotal advancement in our pursuit to catch cancer at its most treatable phase,” said Aaron Elliott, Ph.D., CEO of Freenome. He believes this partnership will fast-track the availability of their CRC blood test to a broader patient population. Furthermore, Freenome will benefit from enhanced funding which can be used to propel the development of its multiomic early cancer detection platform.
Exact Sciences' CEO, Kevin Conroy, echoed these sentiments, highlighting that this partnership will broaden access to unscreened patients by integrating Freenome's technology with the ExactNexus™ platform. This further enables accelerated expansion and significant advancements in cancer care.
Financial Outlook and Future Developments
The partnership's financial structure is comprehensive. It includes an upfront payment of $75 million alongside milestone payments totaling $200 million, contingent upon receiving FDA approval for the innovative blood test. Furthermore, Freenome stands to gain a substantial royalty on test sales, expected to rise to 10% as gross margins achieve set benchmarks. An additional $20 million allocated for joint research and development over three years underscores the commitment to advancing cancer detection technologies.
Riley Ennis, Freenome's co-founder and chief product officer, expressed optimism about the collaboration's potential impact. The objective remains clear: enhance current screening approaches and expedite the development of over ten other cancer types that Freenome is exploring.
Significance of Early Detection in Colorectal Cancer
Colorectal cancer remains one of the leading causes of cancer mortality, with recent statistics showing more than 50,000 annual deaths in the U.S. alone. When diagnosed early, the survival rate exceeds 90%, illustrating the critical importance of effective screening strategies.
Freenome’s advanced blood test aims to facilitate easier and more accessible colorectal cancer screening, providing alternatives that could significantly reduce the number of patients who fall outside regular screening parameters.
About Freenome
Freenome is dedicated to transforming the landscape of early cancer detection through a multiomics platform. This system integrates genetic, epigenetic, and proteomic data, employing AI-driven models to discern cancer-specific markers in the bloodstream. This method not only applies to colorectal cancer but is also being expanded to include a range of other cancers, all with the goal of enhancing accessibility and accuracy in cancer detection.
By focusing on personalized early detection, Freenome plans to offer tailored cancer screening solutions that cater to individual risk profiles, leveraging its partnership with healthcare organizations to ensure widespread availability of its tests. Freenome, headquartered in California, continues its mission to make comprehensive cancer screening a standard part of healthcare.
Frequently Asked Questions
What is the primary focus of the partnership between Freenome and Exact Sciences?
The partnership aims to commercialize Freenome's blood-based screening test for colorectal cancer and enhance market access through Exact Sciences' established infrastructure.
How much is the license agreement worth?
The agreement is valued at up to $885 million, depending on reaching specific regulatory milestones.
When is the commercial launch of Freenome's blood test expected?
The commercialization is anticipated for the year 2026, following FDA approval.
What type of data will enhance Freenome's platform?
Real-world patient data and multimodal molecular data will improve Freenome's AI and machine learning models for cancer detection.
Why is early detection important for colorectal cancer?
Early detection significantly increases the survival rate of colorectal cancer, which can exceed 90% when diagnosed at the earliest stages.
